Home >> Research Area >>Natural Products>>Triterpenoids>> 20(R)-Ginsenoside Rg3

20(R)-Ginsenoside Rg3

CAS# 38243-03-7

20(R)-Ginsenoside Rg3

Catalog No. BCN5018----Order now to get a substantial discount!

Product Name & Size Price Stock
20(R)-Ginsenoside Rg3: 5mg $29 In Stock
20(R)-Ginsenoside Rg3: 10mg Please Inquire In Stock
20(R)-Ginsenoside Rg3: 20mg Please Inquire Please Inquire
20(R)-Ginsenoside Rg3: 50mg Please Inquire Please Inquire
20(R)-Ginsenoside Rg3: 100mg Please Inquire Please Inquire
20(R)-Ginsenoside Rg3: 200mg Please Inquire Please Inquire
20(R)-Ginsenoside Rg3: 500mg Please Inquire Please Inquire
20(R)-Ginsenoside Rg3: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of 20(R)-Ginsenoside Rg3

Number of papers citing our products

Chemical structure

20(R)-Ginsenoside Rg3

3D structure

Chemical Properties of 20(R)-Ginsenoside Rg3

Cas No. 38243-03-7 SDF Download SDF
PubChem ID 46887680 Appearance White powder
Formula C42H72O13 M.Wt 785.02
Type of Compound Triterpenoids Storage Desiccate at -20°C
Solubility DMSO : 41.67 mg/mL (53.08 mM; Need ultrasonic)
Chemical Name (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)O)C
Standard InChIKey RWXIFXNRCLMQCD-CZIWJLDFSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 20(R)-Ginsenoside Rg3

The roots of Panax ginseng C. A. Mey.

Biological Activity of 20(R)-Ginsenoside Rg3

Description20(R)-Ginsenoside Rg3 has anticarcinogenic, neuroprotective, anti-aging and antifatigue activities, it has a wide spectrum of targets including caspase-3, MMP-2, MMP-9,HIF-1α,VEGF,IL-1,IL-6 and TNF-α.
TargetsVEGFR | MMP(e.g.TIMP) | FLT3 | SOD | Bcl-2/Bax | Caspase | Akt | PI3K | HIF | TNF-α | IL Receptor
In vitro

The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell.[Pubmed: 15806969]

Zhongguo Zhong Yao Za Zhi. 2005 Mar;30(5):357-60.

To study the effect of 20(R)-Ginsenoside Rg3 on the expressions of angiogenesis factors proteins (VEGF,bFGF, MMP-2) in human lung adenocarcinoma cell line A549 and HUVEC304 cell.
METHODS AND RESULTS:
The cell lines of A549 and HUVEC304 were cultured with 20(R)- Rg3. The gray scale and positive rate of VEGF, bFGF, MMP-2 were detected by immunohistochemistry. The differential expressions of genes were studied by DNA microarray. The positive rate of VEGF protein in A549 cell decreased significantly as compared with the control group ( P = 0.03). The gray scales of VEGF, Flt, KDT proteins in both A549 cell lines and HUVEC 304 cell lines decreased ( P = 0.05). Gray scale of MMP-2 also decreased in A549 cell lines. The result of differential expressions of genes of A549 cell lines showed that 14 genes were down-regulated and 10 genes were up-regulated.
CONCLUSIONS:
The Chinese materia medica of 20(R)-Rg3 can inhibit the expression of angiogenesis factors proteins via several target genes in both tumour cell and vascular endothelial cell.

20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.[Pubmed: 28709827 ]

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3867-3871.

As shown in our previous studies, 20(R)-Ginsenoside Rg3 [20(R)-Rg3] exerts a neuroprotective effect on a rat model of transient focal cerebral ischemia, and the mechanism through which it decreases the mRNA expression of calpain I and caspase-3 has been delineated. However, researchers do not know whether 20(R)-Rg3 exhibits a neuroprotective effect following oxygen-glucose deprivation and reperfusion (OGD/R) injury in vitro.
METHODS AND RESULTS:
In the present study, 20(R)-Rg3 increased cell viability, decreased the LDH leakage rate, and inhibited the apoptosis rate in a concentration-dependent manner. In addition, 20(R)-Rg3 markedly decreased cleaved caspase-3 protein expression. Furthermore, 20(R)-Rg3 significantly decreased the Bax mRNA and protein levels and increased the levels of Bcl-2 mRNA and protein, subsequently decreasing the Bax/Bcl-2 protein ratio.
CONCLUSIONS:
Based on these findings, 20(R)-Rg3 exerts a neuroprotective effect against OGD/R-induced apoptosis.

In vivo

The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration.[Pubmed: 18981567]

Biol Pharm Bull. 2008 Nov;31(11):2024-7.

20(R)-Ginsenoside Rg3 (20(R)-Rg3) has shown multiple pharmacological activities and been considered as one of the most promising approaches for fatigue treatment. However, 20(R)-Ginsenoside Rg3 has a low bioavailability after oral administration in human due to the first-pass effect. Recently, nasal route has gained increasing interest as it can avoid first-pass effect for its lower enzymatic activity compared with the gastrointestinal tract and liver. In order to provide an animal experimental evidence of 20(R)-Ginsenoside Rg3 intranasal administrated preparation, the anti-fatigue effect of 20(R)-Ginsenoside Rg3 after intranasal administration was investigated.
METHODS AND RESULTS:
Two weeks after 20(R)-Ginsenoside Rg3 was administrated intranasally to mice at three different doses, the anti-fatigue effect of 20(R)-Ginsenoside Rg3 was evaluated by the weight-loaded swimming test and biochemical parameters related to fatigue, such as serum urea nitrogen (SUN), lactic dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), blood lactic acid (LA) and hepatic glycogen.
CONCLUSIONS:
Our results predicted a benefit of 20(R)-Ginsenoside Rg3 as an anti-fatigue treatment by intranasal administration. The mechanism was related to the increase of the storage of hepatic glycogen, and the decrease of the accumulation of metabolite such as lactic acid and serum urea nitrogen.

Protocol of 20(R)-Ginsenoside Rg3

Kinase Assay

Studies of 20(R)-ginsenoside Rg3 on Reversal Multidrug Resistance (MDR) and Induction of Apoptosis in K562/ADM Cell Line[Reference: WebLink]

Effects of 20(R)-Ginsenoside Rg3on Apoptosis of Human Glioma U87 Cells.[Reference: WebLink]

Journal of Chengdu Medical College,2014,9(1) :4-7

To examine the effects of 20(R)-Ginsenoside Rg3on apoptosis of human glioma U87 cells.
METHODS AND RESULTS:
The cytotoxic effect of Rg3on human glioma U87cells was determined with varying concentration of Rg3by MTT assay and flow-cytometric analysis.Morphological characteristics of apoptosis was measured by acridine organe/ethidium bromide assays.Alterations in signaling events were determined with Western Blot analysis probing for Bcl-2,Bax,p-Akt and t-Akt. Using the human glioma U87cell line,Rg3treatment resulted in dose-dependent and time-dependent inhibition of cellular proliferation and the Rg3treatment resulted in induction of apoptosis in dose-dependent manner.As shown by PI and annexin V method,we found that Rg3caused a dosage dependent increase in U87cell apoptosis.As shown by immunoblot analysis,Rg3could cause the downregulation of p-Akt protein expression without an effect on total t-Akt expression and also result in a dose-dependent decrease in antiapoptotic Bcl-2and a concomitant increase in proapoptic Bax proteins.The ratio of Bax/Bcl-2was significantly increased in a dose-dependent manner with Rg3treatment.
CONCLUSIONS:
The study suggests that Rg3 causes an inhibition of phosphatidylinositol 3'-kinase/Akt activation that,in turn,results in modulatons in Bcl-2 family proteins in such a way that the apoptosis of U87cells are regulated.

Progress of Anatomical Sciences,2002, 8(1):31-35.

To observe and study the mechanism of reversing multidrug resistance (MDR) of K562/ADM cell line by a new anti plasma drug 20(R)-Ginsenoside Rg3.
METHODS AND RESULTS:
MTT was applied to determine the cytotoxicity of ADM and Rg3 to K562/ADM cell; The concentration of ADM in K562/ADM cell was detected by fluorescence spectrophotometer; The apoptosis rate and quantity of K562/ADM expressing P glycoprotein(Pgp) were tested by flow cytometry (FCM); Transmission electron microscope (TEM) was used to observe apoptotic K562/ADM cells and apoptotic bodies. (1) The resistance of K562/ADM cell to ADM was 11 times as high as K562 cell was. IC 50 value of Rg3 on K562 and K562/ADM cell were 10.49±0.30μg/ml and 11.76±0.33μg/ml respectively. There wasn

20(R)-Ginsenoside Rg3 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

20(R)-Ginsenoside Rg3 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 20(R)-Ginsenoside Rg3

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.2739 mL 6.3693 mL 12.7385 mL 25.4771 mL 31.8463 mL
5 mM 0.2548 mL 1.2739 mL 2.5477 mL 5.0954 mL 6.3693 mL
10 mM 0.1274 mL 0.6369 mL 1.2739 mL 2.5477 mL 3.1846 mL
50 mM 0.0255 mL 0.1274 mL 0.2548 mL 0.5095 mL 0.6369 mL
100 mM 0.0127 mL 0.0637 mL 0.1274 mL 0.2548 mL 0.3185 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 20(R)-Ginsenoside Rg3

[Anticarcinogenic effect of 20(R)-ginsenoside Rg3 on induced hepatocellular carcinoma in rats].[Pubmed:15807271]

Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Mar;36(2):217-20.

OBJECTIVE: To explore the anticarcinogenic mechanism of 20(R)-Ginsenoside Rg3 in induced liver tumor in SD rat. METHODS: Thirty-five SD rats with induced hepatocellular carcinoma were divided into a control group and 3 dosage groups according to the dosing levels of 20(R)-Ginsenoside Rg3. The tumour volume was measured by MR imaging. The apoptotic rat and S-phase fraction and diploid of tumor cell were measured with flow cytometry. Protein expression of PCNA and TNF were evaluated with immunohistochemistry. RESULTS: There was significant difference in tumour volume between the high dosage group and the control group. The average apoptotic rates were 11.08+/-3.78, 13.57+/-3.34, 27.35+/-16.04 and the S-phase fractions were 23.98+/-9.44, 19.73+/-6.62, 14.09+/-3.48 in the low-, medium-, and high-dosage groups respectively. The apoptotic rate was significantly higher in the high-dosage group than in the medium-dosage group and low-dosage group. Before-after comparison showed that the anti-proliferative effects of 20(R)-Ginsenoside Rg3 were significant in three treatment groups. The higher positive rats of protein expression with PCNA and TNF were significant difference in the high-dosage group compared to those in the low-dosage group. No significant difference between the medium-dosage group and the low-dosage group. CONCLUSION: 20(R)-Ginsenoside Rg3 can noticeably inhibit the proliferation of tumor cells, and efficaciously induce the apoptosis and facilitate necrosis of the tumor cells, and there appears to be a dose dependent effect.

Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities.[Pubmed:11824558]

Biol Pharm Bull. 2002 Jan;25(1):58-63.

When ginsenoside Rg3 was anaerobically incubated with human fecal microflora, all specimens metabolized ginsenoside Rg3 to ginsenoside Rh2 and protopanaxadiol. The main metabolite was ginsenoside Rh2. 20(S)-ginsenoside Rg3 was quickly transformed to 20(S)-ginsenoside Rh2 or 20(S)-protopanaxadiol in an amount 19-fold that compared with the transformation of 20(R)-Ginsenoside Rg3 to 20(R)-ginsenoside Rh2 or 20(R)-protopanaxadiol. Among the bacteria isolated from human fecal microflora, Bacteroides sp., Eubacterium sp., and Bifidobacterium sp. metabolized ginsenoside Rg3 to protopanaxadiol via ginsenoside Rh2. However, Fusobacterium sp. metabolized ginsenoside Rg3 to ginsenoside Rh2 alone. Among ginsenoside Rg3 and its metabolites, 20(S)-protopanaxadiol and 20(S)-ginsenoside Rh2 exhibited the most potent cytotoxicity against tumor cell lines, 20(S)- and 20(R)-protopanaxadiols potently inhibited the growth of Helicobacter pylori, and 20(S)-ginsenoside Rh2 inhibited H+/K+ ATPase of rat stomach.

The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration.[Pubmed:18981567]

Biol Pharm Bull. 2008 Nov;31(11):2024-7.

20(R)-Ginsenoside Rg3 (20(R)-Rg3) has shown multiple pharmacological activities and been considered as one of the most promising approaches for fatigue treatment. However, 20(R)-Rg3 has a low bioavailability after oral administration in human due to the first-pass effect. Recently, nasal route has gained increasing interest as it can avoid first-pass effect for its lower enzymatic activity compared with the gastrointestinal tract and liver. In order to provide an animal experimental evidence of 20(R)-Rg3 intranasal administrated preparation, the anti-fatigue effect of 20(R)-Rg3 after intranasal administration was investigated. Two weeks after 20(R)-Ginsenoside Rg3 was administrated intranasally to mice at three different doses, the anti-fatigue effect of 20(R)-Rg3 was evaluated by the weight-loaded swimming test and biochemical parameters related to fatigue, such as serum urea nitrogen (SUN), lactic dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), blood lactic acid (LA) and hepatic glycogen. The results showed that compared with the negative control group, the intermediate-dose and the high-dose groups significantly prolonged the weight-loaded swimming time (p<0.05; p<0.01), and also increased the hepatic glycogen levels (p<0.05); SUN levels were decreased considerably in three 20(R)-Rg3-treated groups (p<0.01). In addition, the low-dose group obviously decreased the content of blood LA (p<0.05). However, the levels of LDH, SOD and MDA did not show a significant change. Our results predicted a benefit of 20(R)-Rg3 as an anti-fatigue treatment by intranasal administration. The mechanism was related to the increase of the storage of hepatic glycogen, and the decrease of the accumulation of metabolite such as lactic acid and serum urea nitrogen.

Description

20(R)-ginsenoside Rg3 (20(R)-Propanaxadiol), one of the active compounds present in ginseng root, has a potent angiosuppressive and antitumor activities.

Keywords:

20(R)-Ginsenoside Rg3,38243-03-7,Natural Products, buy 20(R)-Ginsenoside Rg3 , 20(R)-Ginsenoside Rg3 supplier , purchase 20(R)-Ginsenoside Rg3 , 20(R)-Ginsenoside Rg3 cost , 20(R)-Ginsenoside Rg3 manufacturer , order 20(R)-Ginsenoside Rg3 , high purity 20(R)-Ginsenoside Rg3

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: